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oo the Editor: Hyperglycemia, with or without pre-existing
iabetes mellitus, is associated with adverse outcomes in patients
ith acute coronary syndromes (1). Whereas blood glucose levels
BGLs) 200 mg/dl are associated with adverse outcomes after
cute myocardial infarction (AMI), the association of moderate
levations or hypoglycemia with cardiovascular mortality in ST-
egment elevation myocardial infarction (STEMI) patients is not
ell characterized. We hypothesized that both hypoglycemia and
oderate elevations of the BGL during STEMI would be associ-
ted with increased rates of adverse outcomes, irrespective of
iabetic status.
Clinical data in STEMI patients were pooled from the Throm-
olysis In Myocardial Infarction (TIMI)-10A/B, Limitation of
yocardial Infarction Following Thrombolysis in Acute Myocar-
ial Infarction (LIMIT-AMI), and Optimal Angioplasty versus
rimary Stenting (OPUS)–TIMI-16 studies (n  4,224). The
rial designs have been previously described. Angiographic data
n  1,260) were available from all trials except OPUS–TIMI-16.
e divided all patients into six groups based on the BGL.
revious studies have focused on severe hyperglycemia (BGL 
99 mg/dl), so previously described (2) definitions of impaired
lucose tolerance (BGL 100 to 125 mg/dl, n 1,229) and diabetes
BGL 126 mg/dl) were used. To determine whether risk
ncreased in parallel with increasingly severe hyperglycemia, pa-
ients with a BGL 126 mg/dl were arbitrarily divided into mild
BGL 126 to 149 mg/dl; n  792), moderate (BGL 150 to 199
g/dl; n  702) and severe (BGL 199 mg/dl; n  598)
yperglycemia. Hypoglycemia was defined as a BGL 81 mg/dl
n 325). A BGL of 81 to 99 mg/dl represented euglycemia (n
78). Admission BGLs were drawn except in the OPUS–
IMI-16 study, where BGLs were drawn 48 h from admission.
ndividual and combined end points of death or recurrent myo-
ardial infarction were analyzed at 30-day follow-up.
Analyses were performed using Stata version 7.0 (Stata Corp.,
ollege Station, Texas) or higher. Continuous variable values are
eported as the mean  SD or median with 25% and 75%
onfidence intervals. Continuous variables were analyzed using the
tudent t test for two-way comparisons and analysis of variance for
2-way comparisons. The chi-square test was used to analyze
ategorical variables. A multivariate logistic regression model for
ortality at 30 days was generated using BGLs of 81 to 99 mg/dl
s the referent group.
Compared with euglycemia, patients with hypoglycemia had lower
ody weight and were more often diabetic. Compared with euglyce-
ia, patients with hyperglycemia were older, with higher heart rates,
revalence of hypertension, congestive heart failure (CHF), and
iabetes, but less tobacco use. Patients with a previous diagnosis of
iabetes accounted for 17.5% of all patients, but they accounted for
9.4% of patients with a BGL199 mg/dl. A BGL126 mg/dl was
resent in 50% of patients without a diagnosis of diabetes.
Higher BGL was associated with a higher TIMI risk score
TRS) for STEMI and TIMI risk index. Higher TIMI risk
ndexes were noted among hyperglycemic but not hypoglycemic
4
(iabetics. Angiographic measures of epicardial flow, myocardial
erfusion, extent of coronary disease, and infarct location were not
ignificantly associated with BGL.
There was a U-shaped relationship between BGL and adverse
utcomes. Death occurred in 4.6% of patients with a BGL 81
g/dl, 4.7% of those with a BGL 199 mg/dl, and 1.0% of those
ith euglycemia (p  0.001). Recurrent MI or death occurred in
0.5% of patients with a BGL 81 mg/dl, 7.2% of those with a
GL199 mg/dl, and 4.2% of those with euglycemia (p 0.001)
Fig. 1A).
igure 1. U-shaped association of admission blood glucose level with death
r recurrent myocardial infarction at 30 days in the overall population (n
,227) (A), nondiabetic patients (n  3,463) (B), and diabetic patients
n  738) (C).
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July 5, 2005:178–83Stratification according to the presence or absence of a previous
iagnosis of diabetes showed that, without diabetes, the combined
nd point of death or recurrent MI was significantly associated
ith BGL (p  0.003; Fig. 1B), and with diabetes there were
ignificant differences in 30-day mortality (p  0.001) and recur-
ent death or MI rates (Fig. 1C) in strata of BGL (p  0.0001).
o significant statistical interaction was identified between BGLs
81 mg/dl or BGLs 199 mg/dl and a history of diabetes (p 
.20 and p  0.23, respectively).
Among those with a TRS4, a U-shaped relationship was seen
etween 30-day mortality and BGL (p  0.001). Those with both
ypoglycemia and TRS 4 had 10-fold higher mortality com-
ared with a similar TRS and euglycemia (22.6% vs. 2.5%;
 0.01) (Fig. 2). A significant interaction between hypoglycemia
nd the TRS was found (odds ratio [OR] 11.2, 95% confidence
nterval [CI] 1.2 to 99.8; p  0.03). Modest increases in BGLs
ere associated with increased mortality in patients with the
ighest TRS (p  0.01). Those with a low (0 to 2) or medium (3
o 4) TRS showed a monotonic rise in adverse outcomes with
ncreasing BGL.
A multivariate logistic regression model using a BGL of 81 to
9 mg/dl as the referent group adjusted for differences among the
ix groups including age, gender, weight, blood pressure, pulse,
ace, smoking status, prior MI, history of hypertension, history of
iabetes, and Killip class. A BGL 81 mg/dl remained associated
ith increased mortality (OR 3.37, 95% CI 1.23 to 9.22, p 
.018), as did a BGL of 150 to 199 mg/dl (OR 2.93, 95% CI 1.17
o 7.33, p  0.021), and BGLs 199 mg/dl (OR 3.09, 95% CI
.15 to 8.31, p  0.026). Mortality was slightly but not signifi-
antly increased with a BGL of 100 to 125 mg/dl and 126 to 149
g/dl. Delays in obtaining BGLs during the OPUS–TIMI-16
rial likely did not influence these findings because the association
f low and high BGL with adverse outcomes persisted after
djustment for the time from symptom onset to randomization and
fter data from this OPUS–TIMI-16 study were excluded.igure 2. Relationship of blood glucose level (BGL) and death at 30 days strati
R  odds ratio.This study builds on previous reports that associate marked
yperglycemia with mortality (3), by demonstrating an exception-
lly poor prognosis with hypoglycemia and milder elevations of
GLs after STEMI, irrespective of a history of diabetes. The
tepwise increase in adverse events associated with moderate BGL
levations further validates the clinical importance of impaired
lucose tolerance and diabetes. The high prevalence of dysglycemia
n nondiabetic patients shows many STEMI patients to be at risk.
similar risk of mortality at one year is noted among diabetic
atients and those newly diagnosed with diabetes during MI (4).
he diagnosis of diabetes, however, during MI is often difficult,
nd diabetes cannot be confirmed, when World Health Organi-
ation guidelines for diagnosis are applied, in over 50% of patients
ho initially present with a BGL 200 mg/dl at the time of
nfarction (5,6). Blood glucose level was associated with adverse
utcomes independent of prior diabetic status, highlighting the
eed for increased recognition of elevated risk among patients with
mpaired glucose metabolism, regardless of whether diabetes has
een diagnosed.
Those with a BGL 81 mg/dl represented only 8% of all
atients with STEMI, but accounted for 13% of all deaths;
owever, little is known regarding the association between hypo-
lycemia and outcomes in STEMI (7). Patients with both an
levated TRS and hypoglycemia had a 10-fold increased mortality
hen compared to those who were euglycemic. Hypoglycemia was
nlikely from medications in this study because only 8.7% of the
ypoglycemic group carried a diagnosis of diabetes, making use of
ypoglycemics improbable in the majority of patients. Hypoglyce-
ic patients may have had hepatic synthetic dysfunction due to
nrecognized disease but acute hepatic congestion from cardio-
enic shock was unlikely because shock was an exclusion criterion
n these trials, and multivariate analysis did not show any relation-
hip between hemodynamic variables and outcome. Alcoholism or
drenal insufficiency may have contributed but was not ascertained.
he extent of coronary disease or efficacy of reperfusion did notfied by Thrombolysis In Myocardial Infarction (TIMI) risk score (TRS).
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July 5, 2005:178–83xplain these findings because these were similar between the
roups.
Current risk stratification scores do not use BGL as a prognostic
ariable. Our findings demonstrate a two- to four-fold increased
isk of death with high or low BGL after STEMI, highlighting an
dditive prognostic value to such models. Specifically, a BGL 81
g/dl was associated with a 3-fold increased risk of death at 30
ays (p  0.01), whereas hypoglycemic patients with a TRS 4,
ad a 11-fold increased risk of death.
Although the Diabetic Insulin-Glucose Infusion in Acute
yocardial Infarction (DIGAMI)-2 trial showed no advantage for
ntensive glucose management (8), a need to identify high-risk
atients with abnormal glucose metabolism remains. The negative
esults may reflect improved overall management of patients
dentified as high-risk. The effect of treating BGL abnormalities
as not assessed in this study, but an understanding of the
echanisms leading to adverse outcomes with mild hyperglycemia
r hypoglycemia in the STEMI population could perhaps lead to
ovel metabolic therapies to improve outcomes.
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etters to the Editor
requency of Cardiac Troponin
Mutations in Families With
ypertrophic Cardiomyopathy in China
read with interest the recent study on the frequency of cardiac
roponin I (cTnI) mutations in families with hypertrophic cardio-
yopathy (HCM) reported from the United Kingdom (1). It is
mazing to note that the prevalence of cTnI mutations in the United
ingdom (3.1%) is almost identical to that in China (3%) (2).
My colleagues from Nanjing (formerly Nanking), China (2),
tudied 71 patients with HCM, 45 male and 26 female, ranging in
ge from 10 to 77 years (average age, 45.5  17.2 years). Exons 7
nd 8 of cTnI gene of the 71 patients and 100 normal controls
ere amplified by polymerase chain reaction (PCR), and the
roducts of PCR were analyzed by direct sequencing. Two
utations of cTnI were identified in 71 patients with HCM (3%)
ut not in the normal controls. Pedigree investigation showed
nother carrier in each family: the cTnIR145W mutation carrier
ad no clinical abnormalities, and the cTnIR162Q carrier had
trial fibrillation when he was in his 20s. Further animal work
sing recombinant cTnIR145W transduction into cultured mouse
dult cardiomyocytes is in progress (2).
Therefore, as Maron (3) recently noted, HCM is indeed an
mportant global disease. Not only is the prevalence of HCM in
hina (0.16%) (4,5) almost the same as in the Western world
0.2%, according to the Coronary Artery Risk Development In
oung Adults [CARDIA] study [6]), but the frequency rates of
TnI mutations are the same (3%) (1,2). This low frequency is
onsistent with that reported from other countries (5%) (5,7).
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